Skip to search formSkip to main contentSkip to account menu

bortezomib

Known as: Bortezomib [Chemical/Ingredient], N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid 
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that… 
National Institutes of Health

Related topics

Related topics

31 relations
Angiogenesis InhibitionBortezomib-Dexamethasone RegimenBortezomib/Cyclophosphamide/Dexamethasone RegimenBortezomib/Dexamethasone/Lenalidomide Regimen

Broader (1)

Antineoplastic Agents

Narrower (4)

LDP-341MLN341PS 341Velcade

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer.
Review
2012
Review
2012
Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
Multiple myeloma (MM) is a life-threatening haematological malignancy for which standard therapy is inadequate. Autologous stem… 
Highly Cited
2007
Highly Cited
2007
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib
PurposeThe body distribution of total radioactivity (TR) and bortezomib was investigated in male Sprague-Dawley rats after single… 
Highly Cited
2006
Highly Cited
2006
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade)1
Proteasome inhibition results in proapoptotic changes in cancer cells, which may make them more sensitive to immune effector… 
2006
2006
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells
Bortezomib (PS-341, Velcade) is a peptide boronate inhibitor of the 20S proteasome that is currently being combined with taxanes… 
Highly Cited
2005
Highly Cited
2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
Bortezomib, a first‐in‐class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma. 
Highly Cited
2004
Highly Cited
2004
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
5F11, a fully human monoclonal antibody directed against CD30, effectively induces killing of CD30-expressing lymphoma cell lines… 
Highly Cited
2003
Highly Cited
2003
Differential Apoptotic Response to the Proteasome Inhibitor Bortezomib (VELCADETM, PS-341) in Bax-Deficient and p21-Deficient Colon Cancer Cells
Targeting the ubiquitin-proteasome pathway has emerged as a promising approach for treating cancer. Bortezomib (VELCADETM… 
Highly Cited
2002
Highly Cited
2002
Chemically modified chiral monolithic silica column prepared by a sol-gel process for enantiomeric separation by micro high-performance liquid chromatography.
Highly Cited
1967
Highly Cited
1967
Investigations of the chymotrypsin-catalyzed hydrolysis of specific substrates. 3. Determination of individual rate constants and enzyme-substrate binding constants for specific amide and ester…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)